Table 3.
Hazard of discontinuing psychosocial treatment by buprenorphine status (n=8516a)
| Hazard Ratio (95% CI) | |
|---|---|
| Buprenorphineb (vs. PSY) | |
| B-PSY | 0.67 (0.62–0.71)c |
| Sex (vs. male) | |
| female | 0.91 (0.86–0.95)c |
| Race (vs. non-White) | |
| white | 0.95 (0.89–1.01) |
| Age (vs. 30+) | |
| <21 | 0.96 (0.88–1.05) |
| 21–24 | 1.10 (1.02–1.19)c |
| 25–29 | 1.03 (0.97–1.09) |
| Urbanicity (vs. central metro) | |
| fringe metro | 1.05 (0.98–1.13) |
| small/med metro | 0.91 (0.84–0.99)c |
| micropolitan | 1.00 (0.92–1.09) |
| rural | 0.92 (0.86–1.00) |
| Eligibility Type (vs. other) | |
| pregnancy | 1.12 (1.02–1.22)c |
| Psych Comorbidity (vs. none) | |
| any | 1.06 (1.01–1.12)c |
| SUD Comorbidity (vs. none) | |
| any | 1.16 (1.10–1.21)c |
| Elixhauser | 1.03 (1.01–1.04)c |
a
17 observations excluded due to missing demographic characteristics
b
PSY, Psychosocial SUD treatment without buprenorphine; PSY-B, Psychosocial SUD treatment with buprenorphine
c
Statistically significant at conventional threshold (p<0.05).